Lantern Pharma
LTRN
22 hedge funds and large institutions have $19.7M invested in Lantern Pharma in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 2 reducing their positions, and 5 closing their positions.
550% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 2
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.52% less ownership
Funds ownership: 12.57% → 12.05% (-0.52%)
8% less funds holding
Funds holding: 24 → 22 (-2)
23% less capital invested
Capital invested by funds: $25.5M → $19.7M (-$5.8M)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
+$2.34M |
| 2 |
Bank of New York Mellon
New York
|
+$232K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$159K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$149K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$93.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FHA
Flagship Harbor Advisors
Boston,
Massachusetts
|
-$2.68M |
| 2 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$887K |
| 3 |
Millennium Management
New York
|
-$764K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$203K |
| 5 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
-$17K |
LTRN Hedge Fund Activity: Q2 2021 in Review
22 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q2 2021, worth a combined $19.7M — down 23% from $25.5M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of LTRN and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 13 added.
The largest buyer was NewEdge Advisors, opening a new position worth an estimated $2.34M. The largest seller was Flagship Harbor Advisors, exiting entirely with an estimated $2.68M sold.
- 22 institutional investors held Lantern Pharma (LTRN) as of Q2 2021, down from 24 in Q1 2021.
- Funds reported $19.7M of Lantern Pharma stock for Q2 2021, down 23% quarter-over-quarter.
- 3 funds opened new Lantern Pharma positions in Q2 2021 and 5 closed out, a net change of -2 holders.
- The largest Lantern Pharma buyer in Q2 2021 was NewEdge Advisors, an estimated $2.34M added.
- The largest Lantern Pharma seller in Q2 2021 was Flagship Harbor Advisors, an estimated $2.68M sold.
Based on aggregated 13F filings for Q2 2021.